{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T03:45:06Z","timestamp":1775706306771,"version":"3.50.1"},"reference-count":50,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T00:00:00Z","timestamp":1558310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although direct\u2010acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection are highly efficacious and safe, treatment initiation is often limited in patients with neuropsychiatric disorders due to concerns over reduced treatment adherence and drug\u2013drug interactions. Here, we report adherence, efficacy, safety and patient\u2010reported outcomes (PROs) from an integrated analysis of registrational studies using the pangenotypic DAA regimen of glecaprevir and pibrentasvir (G\/P). Patients with chronic HCV genotypes 1\u20106 infection with compensated liver disease (with or without cirrhosis) receiving G\/P for 8, 12 or 16\u00a0weeks were included in this analysis. Patients were classified as having a psychiatric disorder based on medical history and\/or co\u2010medications. Primary analyses assessed treatment adherence, efficacy (sustained virologic response at post\u2010treatment week 12; SVR12), safety and PROs. Among 2522 patients receiving G\/P, 789 (31%) had a psychiatric disorder with the most common diagnoses being depression (64%; 506\/789) and anxiety disorders (27%; 216\/789). Treatment adherence was comparably high (&gt;95%) in patients with and without psychiatric disorders. SVR12 rates were 97.3% (768\/789; 95% CI\u00a0=\u00a096.2\u201098.5) and 97.5% (1689\/1733; 95% CI\u00a0=\u00a096.7\u201098.2) in patients with and without psychiatric disorders, respectively. Among patients with psychiatric disorders, SVR12 rates remained &gt;96% by individual psychiatric diagnoses and co\u2010medication classes. Overall, most adverse events (AEs) were mild\u2010to\u2010moderate in severity with serious AEs and AEs leading to G\/P discontinuation occurring at similarly low rates in both patient populations. In conclusion, G\/P treatment was highly efficacious, well\u2010tolerated and demonstrated high adherence rates in patients with chronic HCV infection and psychiatric disorders.<\/jats:p>","DOI":"10.1111\/jvh.13110","type":"journal-article","created":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T15:53:38Z","timestamp":1555084418000},"page":"951-960","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy and safety of glecaprevir\/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis"],"prefix":"10.1111","volume":"26","author":[{"given":"David","family":"Back","sequence":"first","affiliation":[{"name":"University of Liverpool Liverpool UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6435-7450","authenticated-orcid":false,"given":"Pamela","family":"Belperio","sequence":"additional","affiliation":[{"name":"U.S. Department of Veterans Affairs VA Palo Alto Healthcare System Palo Alto California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Bondin","sequence":"additional","affiliation":[{"name":"AbbVie Inc North Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Negro","sequence":"additional","affiliation":[{"name":"University of Geneva Geneva Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5565-7515","authenticated-orcid":false,"given":"Andrew H.","family":"Talal","sequence":"additional","affiliation":[{"name":"Jacobs School of Medicine and Biomedical Sciences University of Buffalo Buffalo New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Park","sequence":"additional","affiliation":[{"name":"AbbVie Inc North Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZhenZhen","family":"Zhang","sequence":"additional","affiliation":[{"name":"AbbVie Inc North Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett","family":"Pinsky","sequence":"additional","affiliation":[{"name":"AbbVie Inc North Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Crown","sequence":"additional","affiliation":[{"name":"AbbVie Inc North Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico J.","family":"Mensa","sequence":"additional","affiliation":[{"name":"AbbVie Inc North Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Marra","sequence":"additional","affiliation":[{"name":"University of Liverpool Liverpool UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,5,20]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i8.2269"},{"issue":"6","key":"e_1_2_8_3_1","first-page":"PCC.09r00877","article-title":"Psychiatric care of the patient with hepatitis C: a review of the literature","volume":"12","author":"Rifai MA","year":"2010","journal-title":"Primary Care Companion to The Journal of Clinical Psychiatry"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i15.1921"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13090"},{"issue":"3","key":"e_1_2_8_6_1","first-page":"259","article-title":"Patient\u2010reported outcomes with direct\u2010acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues","volume":"11","author":"Marcellin F","year":"2017","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1346609"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.07.002"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13638"},{"key":"e_1_2_8_10_1","unstructured":"AASLD.HCV Guidance: Recommendations for Testing Managing and Treating Hepatitis C.2017."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.026"},{"issue":"5","key":"e_1_2_8_12_1","first-page":"685","article-title":"From care to cure: demonstrating a model of clinical patient navigation for hepatitis C care and treatment in high\u2010need patients","volume":"64","author":"Ford MM","year":"2017","journal-title":"Clin Infect Dis"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14328"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i9.1618"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30171"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02558-16"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01620-17"},{"key":"e_1_2_8_18_1","unstructured":"European Public Assessment Report (EPAR): glecaprevir and pibrentasvir.2017."},{"key":"e_1_2_8_19_1","unstructured":"MAVYRET (glecaprevir and pibrentasvir) [package insert]. AbbVie. North Chicago IL."},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29081"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29671"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.039"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702417"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.09.027"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30496-6"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704053"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy220"},{"issue":"2","key":"e_1_2_8_28_1","first-page":"197","article-title":"Real\u2010world data on safety and effectiveness of glecaprevir\/pibrentasvir for the treatment of patients with chronic hepatitis C virus infection: updated data from the German Hepatitis C\u2010Registry","volume":"25","author":"Cornberg M","year":"2018","journal-title":"J Viral Hepatitis"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(18)30351-9"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2017.106"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13038"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v8.i31.1318"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix682"},{"key":"e_1_2_8_34_1","unstructured":"GrebelyJ DoreGJ AlamiNN et al.Safety and Efficacy of Glecaprevir\/Pibrentasvir in Patients with Chronic HCV Genotypes 1\u20106 Receiving Opioid Substitution Therapy. International Network on Hepatitis in Substance Users (INHSU) New York NY 2017."},{"issue":"1","key":"e_1_2_8_35_1","first-page":"636","article-title":"Safety and efficacy of Glecaprevir\/Pibrentasvir in patients with chronic hepatitis C genotypes 1\u20136 and recent drug use","volume":"66","author":"Foster GR","year":"2017","journal-title":"Hepatology"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125318804364"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000903"},{"issue":"1","key":"e_1_2_8_38_1","first-page":"114A","article-title":"Adherence to pangenotypic Glecaprevir\/Pibrentasvir treatment and SVR12 in HCV\u2010infected patients: an integrated analysis of the phase 2\/3 clinical trial program","volume":"66","author":"Brown AS","year":"2017","journal-title":"J Hepatol"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13514"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.08.015"},{"key":"e_1_2_8_41_1","unstructured":"ZEPETIER (elbasvir and grazoprevir) [package insert]. Merck & Co. Whitehouse Station NJ."},{"key":"e_1_2_8_42_1","unstructured":"EPCLUSA (sofosbuvir and velpatasvir) [package insert]. Gilead Sciences Inc. Foster City CA."},{"key":"e_1_2_8_43_1","unstructured":"HARVONI (ledipasvir and sofosbuvir) [package insert]. Gilead Sciences Inc. Foster City CA."},{"key":"e_1_2_8_44_1","unstructured":"VIEKIRA XR (dasabuvir ombitasvir paritaprevir and ritonavir)[package insert]. AbbVie. North Chicago IL."},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30009-7"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.02.042"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw496"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12554"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13462"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix681"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13110","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.13110","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T04:53:38Z","timestamp":1694321618000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.13110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,20]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1111\/jvh.13110"],"URL":"https:\/\/doi.org\/10.1111\/jvh.13110","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,20]]},"assertion":[{"value":"2018-09-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}